Anti-VHL, NT (Von Hippel-Lindau Disease Tumor Suppressor, pVHL, Protein G7)

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of VHL gene is the basis of familial inheritance of VHL syndrome. The protein is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Applications: Suitable for use in ELISA, Immunohistochemistry, Flow Cytometry, Immunofluorescence and Western Blot. Other applications not tested. Recommended Dilution: Western Blot: 1:1000, Immunohistochemistry (Paraffin): 1:10-1:50, Immunofluorescence: 1:10-1:50, Flow Cytometry: 1:10-1:50, Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.